Imris (IMRS)
Imris Debt to Equity Ratio: 0.00
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
IMRS Debt to Equity Ratio Rankings
| Overall | 99th percentile | 1 of 4259 |
| Sector | 99th percentile | 1 of 476 in Healthcare |
| Industry | 98th percentile | 1 of 64 in Medical Instruments & Supplies |
IMRS Debt to Equity Ratio Range, Past 5 Years
| Minimum | 0.00 | Dec 2008 |
| Maximum | 0.013 | Sep 2007 |
| Average | 0.0011 |
About Debt to Equity Ratio
YCharts Calculation: Debt to Equity = (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity
The debt to equity ratio is a leverage ratio indicating the relative proportion of shareholders' equity and debt used to finance a company's assets. It reveals how a company has financed its assets. A low debt to equity ratio indicates lower risk because shareholder's have claims on a larger portion of the company's assets.
A high debt to equity ratio usually means that a company has been aggressive in financing growth with debt and often results in volatile earnings.
It is also known as Debt/Equity Ratio, Debt-Equity Ratio, and D/E Ratio.
Learn More
You may also be interested in these IMRS related companies
IMRS News
$IMRS Canaccord reiterates a 'buy' and $4.50 target on IMRS! http://stks.co/3pfG
about 14 days ago by porsche17000
about 14 days ago by porsche17000
Canaccord Genuity Adjusting Estimates on Imris Inc. (IMRS); Bookings and Margins Up
May 15, 8:50AM Street Insider
May 15, 8:50AM Street Insider
$IMRS Neuroarm FDA filing ahead of schedule in July 2012. Gonna be firing on all cylinders again. Hospital spending getting back to normal.
about 15 days ago by porsche17000
about 15 days ago by porsche17000
$IMRS Super bullish going forward. Graves upbeat. Backlog growing. Revs to grow sequentially each Q this year. 2012 bookings $80-100M!
about 15 days ago by porsche17000
about 15 days ago by porsche17000
$IMRS Back order looks good, i assume its where it is now due to the delays but will double by years end? Not sure how this will trade now
about 15 days ago by GArgondizza
about 15 days ago by GArgondizza
$IMRS forms bullish "Continuation Wedge" chart pattern. http://stks.co/3mUI
about 19 days ago by RecogniaEvents
about 19 days ago by RecogniaEvents
$IMRS - Out of favor here thus the opportunity. One year from now this could be 5 - 10 times the price. We'll have volume then.
about 19 days ago by porsche17000
about 19 days ago by porsche17000
$IMRS New Milestones In Visius Surgical Theatre By Imris.
http://stks.co/3kRE
about 20 days ago by porsche17000
about 20 days ago by porsche17000
IMRIS To Hold First Quarter 2012 Results Conference Call And 2012 Annual General Meeting
May 07, 10:16AM PR Newswire
May 07, 10:16AM PR Newswire
$IMRS Techna Institute...http://technainstitute.com/resources-places/mrgrt/
about 22 days ago by porsche17000
about 22 days ago by porsche17000
$IMRS is up 7.23% today (Stock twits page stuck on Friday ticker quote).
about 29 days ago by abubnic
about 29 days ago by abubnic
$IMRS Whens this dog gonna turn around? Nothing like great news and no upside..
about 35 days ago by GArgondizza
about 35 days ago by GArgondizza
Great news story shows tumor removal in action using $IMRS Visius Surgical Suite. http://stks.co/3Owa
about 41 days ago by abubnic
about 41 days ago by abubnic
Download "Summary of the First Published Results" of $IMRS VISIUS Surgical Theatre" http://stks.co/3Or6
about 41 days ago by abubnic
about 41 days ago by abubnic
$IMRS Results of Randomized Trial w High-Field Intraoperative MR Imaging Presented at Major Neurosurgical Conference. http://stks.co/3Oqz
about 41 days ago by abubnic
about 41 days ago by abubnic
$IMRS results of 1st randomized trial-resection of low-grade insular glioma using high-field intraoperative MR imaging. http://stks.co/3Oqo
about 41 days ago by abubnic
about 41 days ago by abubnic
Study shows significantly greater extent of tumor resection, better rates of total resection and better long-term morbidity w $IMRS.
about 41 days ago by abubnic
about 41 days ago by abubnic
Clinical Data Shows Patient Benefit of VISIUS Surgical Theatre by $IMRS. http://stks.co/3OqV
about 41 days ago by abubnic
about 41 days ago by abubnic
$IMRS Studies continue to confirm VISIUS benefits...http://finance.yahoo.com/news/clinical-data-shows-patient-benefit-151500896.html
about 41 days ago by porsche17000
about 41 days ago by porsche17000
$IMRS Clinical Applications/Future Direction of iMRI in Neurosurgery. Satellite symposium tonight from 6:30-9:30 pm. http://stks.co/3MQv
about 43 days ago by abubnic
about 43 days ago by abubnic
Canaccord Genuity Reiterates a 'Buy' on Imris Inc. (IMRS); Q1 Bookings Help Validate Funnel
Mar 02, 9:40AM Street Insider
Mar 02, 9:40AM Street Insider
Imris, Inc. (IMRS) Reports Q4 Loss of $0.11, Offers FY12 Sales Guidance
Mar 01, 4:24PM Street Insider
Mar 01, 4:24PM Street Insider
Canaccord Genuity Maintains a 'Buy' on Imris Inc. (IMRS); Q3 Missed, but Not as Bad as Feared
Nov 15, 8:52AM Street Insider
Nov 15, 8:52AM Street Insider
Imris, Inc. (IMRS) Misses Q3 EPS by 14c; Guides FY11 Revs Below Street
Nov 14, 4:15PM Street Insider
Nov 14, 4:15PM Street Insider
Canaccord Genuity Maintains a 'Buy' on IMRIS (IMRS); Lowering Estimates and Price Target
Oct 11, 8:41AM Street Insider
Oct 11, 8:41AM Street Insider
IMRIS (IMRS), MDA Enter Multimillion MR Guided Surgical Robot Collaboration
Sep 19, 4:38PM Street Insider
Sep 19, 4:38PM Street Insider
Imris anticipates strengthening of booking performance in second half of FY11
Aug 09, 5:25PM FlyOnTheWall
Aug 09, 5:25PM FlyOnTheWall
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| IMRS | 3.17 | +0.05 | +1.60% | 142.68M |
| IMOS | 13.17 | +0.58 | +4.61% | 338.92M |
| IMO | 41.35 | +0.91 | +2.25% | 34.28B |
| IMN | 5.71 | +0.16 | +2.88% | 212.73M |
| IDSA | 5.13 | -0.02 | -0.39% | 35.74M |
| IDRA | 1.00 | -0.02 | -1.96% | 27.64M |
| IDN | 1.64 | -0.09 | -5.07% | 47.44M |
| IDIX | 9.41 | -0.27 | -2.79% | 1.041B |
| IDI | 1.85 | -0.03 | -1.60% | 38.59M |
| IDCC | 25.28 | +0.14 | +0.56% | 1.134B |
